{
    "clinical_study": {
        "@rank": "138096", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and\n      effective in lowering the amount of HIV in the blood of patients who have been treated with\n      more than 1 protease inhibitor (PI)."
        }, 
        "brief_title": "ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "All patients take ABT-378/ritonavir and efavirenz; there are no placebos in this study.\n      Patients take study medications for 48 weeks, during which time there will be 15 study\n      visits. There is a possibility of a study extension after 48 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients may be eligible for this study if they:\n\n          -  Are HIV-positive.\n\n          -  Have a viral load (level of HIV in the blood) of at least 1,000 copies/ml.\n\n          -  Have been receiving stable (no changes) anti-HIV treatment that includes at least 1\n             PI for at least 8 weeks prior to study entry.\n\n          -  Have received more than 1 PI for at least 12 weeks each at some time in the past.\n\n        Exclusion Criteria\n\n        Patients will not be eligible for this study if they:\n\n          -  Have had any active opportunistic (AIDS-related) infections within the past 30 days.\n\n          -  Have ever received nonnucleoside reverse transcriptase inhibitors (NNRTIs), such as\n             delavirdine, nevirapine, or efavirenz.\n\n          -  Have received certain medications.\n\n          -  Are pregnant or breast-feeding.\n\n          -  Abuse alcohol or drugs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004582", 
            "org_study_id": "285E", 
            "secondary_id": "M98-957"
        }, 
        "intervention": [
            {
                "intervention_name": "Lopinavir/Ritonavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Efavirenz", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Protease Inhibitors", 
                "Ritonavir", 
                "Lopinavir", 
                "HIV Protease Inhibitors", 
                "Reverse Transcriptase Inhibitors", 
                "Efavirenz"
            ]
        }, 
        "keyword": [
            "HIV Protease Inhibitors", 
            "Ritonavir", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "Viral Load", 
            "ABT 378", 
            "efavirenz"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94103"
                }, 
                "name": "ViRx Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Study of ABT-378/Ritonavir and Efavirenz in Multiple Protease Inhibitor-Experienced Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004582"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ViRx", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2000"
    }, 
    "geocoordinates": {
        "ViRx Inc": "37.775 -122.419"
    }
}